Status:
COMPLETED
Anti-factor Xa Based Venous Thromboembolism Prophylaxis
Lead Sponsor:
Meir Medical Center
Conditions:
Dose Adjustment of Enoxaparin in ICU Patients
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Introduction: Venous thromboembolism (VTE) in the intensive care unit (ICU) is associated with significant morbidity and mortality therefore prevention is imperative to reduce its burden. VTE prophyla...
Eligibility Criteria
Inclusion
- Inclusion criteria were age over 18 years and a predicted ICU stay of more than 72 h.
- \-
Exclusion
- Exclusion criteria were any contraindication for heparin-based thromboembolic prophylaxis, patients with an indication for therapeutic anticoagulation , administration of unfractioned-heparin or low-molecular-weight-heparin prior to study entry, active hemorrhage, or creatinine clearance \< 30 mL/min.
- \-
Key Trial Info
Start Date :
June 23 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 15 2021
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05221879
Start Date
June 23 2019
End Date
February 15 2021
Last Update
February 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meir Medical Center
Kfar Saba, Israel